Dyne Therapeutics (NASDAQ:DYN) Shares Up 4% - What's Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s stock price shot up 4% during trading on Monday . The stock traded as high as $8.24 and last traded at $8.49. 40,225 shares changed hands during trading, a decline of 97% from the average session volume of 1,483,034 shares. The stock had previously closed at $8.17.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on DYN shares. Scotiabank began coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price target on the stock. BMO Capital Markets initiated coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They set an "outperform" rating and a $50.00 target price on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. HC Wainwright reiterated a "buy" rating and issued a $46.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. Finally, Chardan Capital restated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $47.46.

Dyne Therapeutics Stock Down 0.5 %

The stock's 50-day simple moving average is $10.79 and its 200 day simple moving average is $19.63. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -3.11 and a beta of 1.21.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. As a group, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 6,237 shares of company stock valued at $77,760 in the last three months. 20.77% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in DYN. GF Fund Management CO. LTD. bought a new position in Dyne Therapeutics in the fourth quarter valued at approximately $50,000. GAMMA Investing LLC increased its holdings in shares of Dyne Therapeutics by 837.5% during the first quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock valued at $251,000 after acquiring an additional 2,345 shares in the last quarter. KBC Group NV raised its stake in shares of Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after purchasing an additional 978 shares during the last quarter. Summit Investment Advisors Inc. increased its position in shares of Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after acquiring an additional 721 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new position in Dyne Therapeutics in the fourth quarter valued at about $205,000. Institutional investors and hedge funds own 96.68% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.